PMID- 33248415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 14
IP  - 1
DP  - 2021 Jan
TI  - Prostatic aspirated cellular RNA analysis enables fast diagnosis and staging of 
      prostate cancer.
PG  - 100963
LID - S1936-5233(20)30455-1 [pii]
LID - 10.1016/j.tranon.2020.100963 [doi]
LID - 100963
AB  - OBJECTIVE: The aim of this study is to investigate the potential application of 
      prostatic aspirated cellular RNA analysis technique for fast diagnosing and 
      staging prostate cancer. METHODS: Prostatic aspirated cells were obtained 
      immediately after transrectal ultrasound (TRUS)-guided needle biopsy. Cellular 
      RNA such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA, prostate 
      specific antigen (PSA) mRNA and prostate-specific RNA (PCA3) mRNA were analyzed 
      by using Reverse Transcription-Polymerase Chain Reaction (RT-PCR). PCA3 score was 
      calculated as the ratio of PCA3 mRNA to PSA mRNA expression. Diagnostic 
      performance of the fast-aspirated cellular RNA analysis technique for determining 
      prostate cancer and metastatic status were evaluated by developing receiver 
      operating characteristic curves (ROC), and the correlation between aspirated 
      cellular RNA mRNA expressions and risk grouping was calculated, to investigate 
      the underlying potential for PCa staging. RESULTS: PCA3 score was significantly 
      higher in prostatic aspirated cells obtained from cancerous tissues than 
      noncancerous tissues. The median aspirated cellular PCA3 score was higher in 
      patients with PCa compared to BPH, and presenting an area under the ROC curve 
      (AUC) of 0.87 (95%CI: 0.79-0.94) for PCa diagnosis. Multivariate regression 
      analysis revealed that baseline median aspirated cellular PCA3 score (OR=9.316, 
      95%CI: 1.045-83.033, P<0.05) was an independent predictive factor for metastatic 
      status in PCa patients. CONCLUSION: The ease of use and minimal complexity of 
      fast prostatic aspirated cellular RNA analysis may be a valuable diagnostic 
      technique, providing urgent diagnostic information for accurate PCa diagnosing 
      and staging.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Sang, Yiwen
AU  - Sang Y
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Wang, Xuchu
AU  - Wang X
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Yu, Pan
AU  - Yu P
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Zhang, Luyan
AU  - Zhang L
AD  - Department of Laboratory Medicine, Ningbo Mingzhou Hospital, Ningbo, China.
FAU - Dai, Yibei
AU  - Dai Y
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Zhang, Lingyu
AU  - Zhang L
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Wang, Danhua
AU  - Wang D
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Liu, Zhenping
AU  - Liu Z
AD  - Department of Laboratory Medicine, Yuhang Branch of the Second Affiliated 
      Hospital of Zhejiang University, Hangzhou, China.
FAU - Wang, Yao
AU  - Wang Y
AD  - Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University, 
      Hangzhou, China.
FAU - Tao, Zhihua
AU  - Tao Z
AD  - Department of Laboratory Medicine, the Second Affiliated Hospital of Zhejiang 
      University, Hangzhou, China. Electronic address: zrtzh@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20201125
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC7704456
OTO - NOTNLM
OT  - Prostate cancer;Aspirated cellular RNA analysis;Cancer diagnosis
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/11/29 06:00
MHDA- 2020/11/29 06:01
PMCR- 2020/11/25
CRDT- 2020/11/28 20:10
PHST- 2020/09/08 00:00 [received]
PHST- 2020/11/15 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2020/11/29 06:00 [pubmed]
PHST- 2020/11/29 06:01 [medline]
PHST- 2020/11/28 20:10 [entrez]
PHST- 2020/11/25 00:00 [pmc-release]
AID - S1936-5233(20)30455-1 [pii]
AID - 100963 [pii]
AID - 10.1016/j.tranon.2020.100963 [doi]
PST - ppublish
SO  - Transl Oncol. 2021 Jan;14(1):100963. doi: 10.1016/j.tranon.2020.100963. Epub 2020 
      Nov 25.